Sermorelin Dosage and Protocol Guide: Injection, Timing, and Cycle (2026)

Executive Summary

Sermorelin dosage and protocol are among the most-searched questions for anyone starting growth hormone peptide therapy — because while sermorelin's mechanism and benefits are relatively well known, guidance on exactly how to take it (how much, when, how often, and for how long) is scattered and inconsistent online. This guide provides a structured protocol breakdown: standard dose ranges, subcutaneous injection technique, timing rationale, cycle structure, stacking strategies, and what labs to monitor.

Sermorelin is a synthetic 29-amino acid peptide that mimics the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and secrete growth hormone (GH) in a pulsatile, physiological pattern — which distinguishes it from direct exogenous HGH administration. Because sermorelin works through the pituitary's own feedback loop, it carries a lower risk of GH oversaturation and is considered a more controlled route to GH optimization. In US telehealth, it is available by prescription from compounding pharmacies and is primarily used for age-related GH decline, body composition, recovery, and sleep quality.

Before diving into protocol specifics: sermorelin is not FDA-approved for adult GH optimization and is available only through licensed US compounding pharmacies via physician prescription. The dosing parameters below reflect commonly prescribed telehealth protocols as of 2026 — they are not a substitute for individualized clinical guidance. Use this guide alongside our provider comparison tool, sermorelin vs HGH comparison, and sermorelin vs ipamorelin vs CJC-1295 guide.

At-a-Glance Comparison

Standard sermorelin dosing parameters by protocol type as of 2026. Individual dosing should be determined by a licensed prescribing provider based on age, IGF-1 levels, goals, and response.

Why Bedtime Dosing Is the Standard: The Nocturnal GH Pulse

Sermorelin's bedtime dosing requirement is mechanistically grounded — not arbitrary. Getting the timing right is as important as getting the dose right. Buyers searching for sermorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The body releases the majority of its daily GH in a series of pulses, with the largest pulse occurring shortly after the onset of deep (slow-wave) sleep — typically 1–2 hours after falling asleep. Sermorelin, as a GHRH analog, stimulates the pituitary to produce and release GH. When administered 30–60 minutes before sleep, its peak action aligns with this natural nocturnal GH window, amplifying the pulse rather than creating a separate isolated signal. The fasted-state requirement is equally important. Insulin and growth hormone are physiologically antagonistic: elevated insulin (from a recent meal) suppresses GH release. Administering sermorelin in the fasted state — at least 2–3 hours after the last meal — removes this suppression and allows the peptide to elicit its full pituitary response. Some providers also prescribe a 5 days on / 2 days off schedule (typically weekdays on, weekends off) to prevent receptor desensitization. Because sermorelin continuously stimulates GHRH receptors at the pituitary, periodic breaks may preserve receptor sensitivity over longer protocols. Key timing rules: (1) dose 30–60 minutes before sleep; (2) do not eat for at least 2 hours before dosing; (3) avoid high-carbohydrate or high-sugar foods in the 2 hours prior; (4) do not administer immediately before intense exercise. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Off-label morning or midday dosing is occasionally used but is significantly less effective than bedtime dosing — it misses the natural GH pulse window and typically delivers a weaker IGF-1 response on labs. Stick to bedtime unless your prescribing provider has a specific reason to deviate. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Subcutaneous Injection Technique: Step-by-Step

Sermorelin is administered exclusively via subcutaneous (SubQ) injection — not intramuscular. The injection delivers peptide into the fat layer just beneath the skin for gradual systemic absorption. Buyers searching for sermorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Step-by-step injection technique: (1) Wash hands thoroughly with soap and water before handling any injectable. (2) Draw the dose: Using a 28–31 gauge insulin syringe (0.5 mL or 1 mL), draw the prescribed volume based on your reconstitution ratio. Example: a 3 mg vial reconstituted with 1.5 mL bacteriostatic water gives 2 mg/mL — each 0.1 mL drawn into the syringe contains 200 mcg. (3) Select injection site: Rotate among abdomen (1–2 inches from navel), upper outer thigh, and upper arm. Rotating sites prevents localized lipodystrophy. (4) Clean the site: Swab with an alcohol pad; allow to air dry completely. (5) Pinch and insert: Pinch a small fold of skin and fat. Insert the needle at a 45° angle (or 90° if fat layer is thick) fully into the pinched fold. (6) Inject slowly: Release the pinch and slowly depress the plunger over 5–10 seconds. Do not aspirate (aspiration is not required for SubQ). (7) Withdraw and apply gentle pressure: Remove the needle at the same angle. Apply gentle pressure with a cotton ball — do not rub, as rubbing disperses the peptide unevenly. (8) Dispose properly: Place the used syringe and needle in a sharps container immediately. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Common mistakes: using an expired or improperly stored reconstituted vial; dosing too close to a meal; injecting into the same site repeatedly without rotation; using needles larger than 27 gauge (stick to 28–31 gauge, ½ inch length). Never inject into a vein — the SubQ technique described avoids this by design. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Stacking Sermorelin: Ipamorelin and CJC-1295 (No DAC)

Sermorelin monotherapy is effective, but combining it with a GHRP (growth hormone-releasing peptide) produces larger, more sustained GH pulses. This two-pathway approach is the dominant protocol in US telehealth as of 2026. Buyers searching for sermorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Sermorelin works exclusively through the GHRH receptor pathway at the pituitary. A complementary GHRP works through a separate receptor — the ghrelin receptor (GHS-R1a) — producing a synergistic GH pulse when combined. The most common stack: sermorelin 0.2–0.3 mg + ipamorelin 100–300 mcg, administered together at bedtime. Ipamorelin is highly selective — it stimulates GH release without significantly elevating cortisol or prolactin, making it the preferred GHRP for clean stacking. The combination produces a larger, more sustained GH pulse than either peptide alone. A secondary stack option: sermorelin + CJC-1295 (no DAC). Both are GHRH analogs (same receptor), so this is not dual-pathway synergy — it is amplified GHRH pathway stimulation. CJC-1295 without DAC has a slightly longer half-life than sermorelin (~30 min vs 10–20 min), extending the duration of each pulse. Use this combination to maximize GHRH-pathway output rather than for two-pathway synergy. Some telehealth providers prescribe a triple stack (sermorelin + CJC-1295 no DAC + ipamorelin) for patients with significantly suppressed IGF-1 or aggressive body composition goals — this is the highest-stimulation approach and requires closer monitoring. Do NOT stack sermorelin with CJC-1295 WITH DAC for daily dosing. CJC-1295 with DAC has an 6–8 day half-life and is dosed once or twice per week — combining it daily with sermorelin can overstimulate the GHRH receptor. CJC-1295 with DAC replaces sermorelin in a protocol, it does not stack with it. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Avoid mixing CJC-1295 with DAC into a daily sermorelin protocol — the extended half-life creates cumulative GHRH receptor stimulation that can lead to desensitization and elevated IGF-1 above the reference range. If your pharmacy compound label says 'CJC-1295,' verify whether it includes DAC before dosing daily. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Lab Monitoring: What to Test and When

Sermorelin protocols require periodic lab work. IGF-1 is the primary monitoring marker — the only objective measure of whether the protocol is producing the intended effect. Buyers searching for sermorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Baseline labs before starting: IGF-1 (insulin-like growth factor 1) is the primary marker — it reflects average GH production over time rather than a single GH pulse, making it more clinically useful than a spot GH level. Also baseline: glucose, hemoglobin A1c (GH can influence insulin sensitivity), CBC, CMP, and lipid panel. Some providers also include IGFBP-3 for a more complete picture. Follow-up labs at 8–12 weeks: repeat IGF-1 to assess response. Target: most telehealth providers aim for IGF-1 in the upper third of the age-adjusted reference range — not above range, which would indicate GH oversaturation. If IGF-1 rises above the age-adjusted range, dose reduction is indicated. Ongoing monitoring (every 3–6 months on active protocols): continue IGF-1 quarterly. Also monitor for clinical signs: fluid retention (edema), joint pain, numbness/tingling (carpal tunnel symptoms), and changes in blood pressure — all are signals that GH stimulation may be too aggressive. Patients with pre-existing cancers, a history of cancer, or active acromegaly are contraindicated for sermorelin and all GHRH analogs. A thorough medical history review before starting is non-negotiable. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common clinical error on sermorelin protocols is not monitoring IGF-1 after initiation. Without follow-up labs, there is no way to know whether the dose is working, whether to titrate up, or whether IGF-1 has exceeded safe range. Do not skip the 8–12 week lab check. For current provider options with lab monitoring included, see our best peptide clinics online (2026). Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What to Expect: Timeline, Results, and Side Effects

Sermorelin produces gradual, physiological improvements — not rapid drug-like effects. Understanding the realistic timeline sets expectations and prevents early abandonment of an effective protocol. Buyers searching for sermorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Timeline of common effects: Sleep quality improvements are often the first effect reported, sometimes within 2–4 weeks — sermorelin's most consistent early signal. Body composition changes (reduced fat mass, increased lean mass) typically emerge at 8–12 weeks and are most pronounced with consistent protocol adherence, adequate protein intake, and resistance training. Recovery and joint comfort improvements tend to parallel body composition changes in timing. Energy and mood improvements are commonly reported but more variable. Cost context: sermorelin compounded through US telehealth ranges from approximately $100–$400/month depending on dose, vial size, and provider — substantially less than pharmaceutical HGH ($500–$2,000+/month). See our sermorelin cost guide (2026) for a full breakdown. Common side effects: injection site reactions (mild redness, itching, swelling — resolves within 30–60 minutes); flushing (transient warm sensation 5–15 minutes post-injection, more common at higher doses); nausea (occasional, more common if not fully fasted — adjust timing to resolve); headache (transient at initiation, resolves within 1–2 weeks); fluid retention (mild edema if IGF-1 rises significantly — monitor and adjust dose); drowsiness (deeper sleep early in protocol — generally viewed as a benefit). A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Serious adverse effects (significant joint pain, carpal tunnel symptoms, glucose intolerance, vision changes) are typically associated with IGF-1 levels above the age-adjusted reference range. Regular monitoring prevents these from developing. Contact your prescribing provider immediately if you experience persistent or significant versions of any of the above symptoms. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you are considering sermorelin for GH optimization, body composition, recovery, or anti-aging, the right first step is a licensed provider consultation with baseline IGF-1 labs. Our provider comparison tool helps you find telehealth clinics that prescribe sermorelin responsibly — with US-licensed compounding pharmacies, written protocols, and follow-up lab monitoring. Our best peptide clinics 2026 guide is a strong starting point for comparing options.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the standard sermorelin dosage?

The most commonly prescribed sermorelin dose in US telehealth is 0.2–0.3 mg (200–300 mcg) per injection, administered once daily via subcutaneous injection at bedtime. Some providers start at 0.1 mg and titrate upward based on IGF-1 response. Doses above 0.5 mg per injection are uncommon in standard protocols. Your prescribing provider will determine the right dose based on your baseline IGF-1, age, weight, and goals.

What is the best time to take sermorelin?

Bedtime dosing — 30–60 minutes before sleep — is the standard protocol. This timing aligns sermorelin's peak action with the body's natural nocturnal growth hormone pulse (which occurs shortly after the onset of deep sleep), maximizing the GH release triggered by the peptide. Administer in a fasted state: at least 2 hours after your last meal to avoid insulin-mediated suppression of GH secretion.

How long does it take for sermorelin to work?

Sleep quality improvements are often the first effect reported, sometimes within 2–4 weeks. Body composition changes (reduced fat, increased lean mass) typically emerge at 8–12 weeks. IGF-1 elevation is usually measurable on labs by the 8–12 week mark. Full protocol response assessment is generally done at 3–6 months. Sermorelin works gradually through physiological GH stimulation — it is not a rapid-result compound.

Can sermorelin and ipamorelin be taken together?

Yes — the sermorelin + ipamorelin stack is one of the most commonly prescribed GH peptide protocols in US telehealth. Sermorelin works via the GHRH receptor pathway; ipamorelin works via the ghrelin receptor (GHS-R1a) pathway. The two mechanisms are synergistic — combining them produces a larger, more sustained GH pulse than either peptide alone. The standard approach is to administer both in the same injection at bedtime.

How do I reconstitute sermorelin?

Sermorelin comes as a lyophilized (freeze-dried) powder in a sealed vial. To reconstitute, use bacteriostatic water — typically 1–2 mL per vial. Example: a 3 mg vial reconstituted with 1.5 mL bacteriostatic water gives a concentration of 2 mg/mL, so each 0.1 mL drawn into a syringe contains 200 mcg. Your compounding pharmacy will provide a reconstitution guide and concentration table. After reconstitution, refrigerate immediately and use within 30 days.

What labs should I monitor on sermorelin?

IGF-1 is the primary monitoring marker — it reflects average GH production and is tested at baseline and at 8–12 weeks into the protocol. Target is typically the upper third of the age-adjusted reference range. Also monitor fasting glucose and HbA1c, particularly for patients with metabolic concerns, since elevated GH can reduce insulin sensitivity. A full CBC, CMP, and lipid panel at baseline provides a comprehensive starting picture.

What is the difference between sermorelin and CJC-1295?

Both sermorelin and CJC-1295 are GHRH analogs that stimulate GH release through the same pituitary receptor pathway. The key difference is half-life. Sermorelin has a half-life of approximately 10–20 minutes, producing a short, sharp GH pulse. CJC-1295 without DAC has a slightly longer half-life (~30 minutes). CJC-1295 with DAC has a half-life of 6–8 days, producing sustained GH elevation with once or twice-weekly dosing. For daily bedtime protocols, sermorelin and CJC-1295 (no DAC) are interchangeable or combinable. CJC-1295 with DAC replaces rather than stacks with sermorelin. See our full comparison guide.

How long should a sermorelin cycle be?

Standard telehealth protocols typically run 3–6 months of active treatment followed by a 1–2 month break. The break helps prevent GHRH receptor desensitization (tachyphylaxis) and allows IGF-1 to return toward baseline before re-evaluating. Some patients cycle 5 days on / 2 days off within each week as well. Long-term ongoing protocols exist but require closer monitoring — typically quarterly IGF-1 testing to ensure levels remain in the age-adjusted reference range.

Is sermorelin better than HGH?

Sermorelin and HGH serve different goals. Direct HGH therapy delivers exogenous growth hormone, producing faster and more pronounced effects — but it suppresses the pituitary's own GH production over time and carries higher risk of side effects at elevated doses. Sermorelin stimulates the pituitary to produce GH naturally, preserving the feedback loop and producing more physiological GH levels. Most anti-aging and body composition patients do well with sermorelin. Patients with documented severe adult GH deficiency (very low IGF-1) may require direct HGH therapy. See our sermorelin vs HGH guide for a full breakdown.

Where can I get sermorelin prescribed online?

Multiple US telehealth providers prescribe sermorelin through licensed compounding pharmacies. The typical process: complete a health questionnaire, provide baseline labs (or get labs through the provider), consult with a physician, and receive your prescription shipped from a compounding pharmacy. See our best peptide clinics online (2026) and provider comparison tool for vetted options with pricing and lab inclusion details.